Friday, November 20, 2026
News

Advent International to buy 'significant' stake in Suven Pharmaceuticals

SocialTwist Tell-a-Friend    Print this Page   COMMENT

Mumbai (Maharashtra) | December 26, 2022 4:01:28 PM IST
Advent International on Monday said it has entered into a definitive agreement to acquire a significant stake in Suven Pharmaceuticals from the Jasti family, subject to regulatory approvals and conditions. However, the company didn't ascertain the amount of the deal.

As part of the transaction, Advent said it would also be making an open offer to acquire an additional 26 per cent of the outstanding equity shares of the company from the public shareholders.

When the acquisition completes, Advent intends to explore the merger of its portfolio company, Cohance Lifesciences with Suven, to build a contract development and manufacturing organisation (CDMO) and merchant active pharmaceutical ingredient (API) player servicing the pharma and speciality chemical markets, according to a statement shared by Suven with exchanges.

The merger will be evaluated by the board taking into consideration the strategic rationale and accretiveness to Suven's public shareholders and will be subject to regulatory approvals and other customary approvals.

"We are delighted to bring Advent into Suven Pharma as a strategic investor. We have built a business with industry-leading growth and margins...Their experience and resources will launch the next phase of growth for Suven pharma. This move will benefit Suven platform immensely. The proposed collaboration with Cohance is a win-win for Suven and its public shareholders," said Venkateswarlu Jasti, Managing Director, Suven Pharmaceuticals.

Suven Pharma, which was demerged from its parent entity, Suven Life Sciences, in 2020, is one of the leaders in the India pharma CDMO space with high growth and profitability, according to the Advent statement.

"We intend to explore a merger of Cohance with Suven in a manner which is synergistic and accretive for Suven's shareholders," said Shweta Jalan, Managing Partner and Head of Advent International in India.

Suven Pharma, which was demerged from its parent entity, Suven Life Sciences, in 2020, is one of the leaders in the India pharma CDMO space with high growth and profitability. (ANI)

 
  LATEST COMMENTS ()
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE BUSINESS NEWS
JPMorgan says third-party vendors target...
Womens Entrepreneurship Day 2026: Celeb...
South Korea's exports cross USD 1 trilli...
SEBI Chairman calls for continuous train...
Haaka Media Enters the Growing Mobile En...
Karnataka leads India's GCC ecosystem wi...
More...
 
INDIA WORLD ASIA
Tripura Congress leader questions State ...
Gorakhpur JCB incident: Victim's father ...
PM Modi calls for greater community part...
Cyclone Akvan: CM Mohan Majhi reviews pr...
Court permits accused research scholar t...
Satya Niketan Building Collapse Case com...
More...    
 
 Top Stories
Ben Shelton beats Jodar in straight... 
JPMorgan says third-party vendors t... 
Gorakhpur JCB incident: Victim's fa... 
"This award belongs to everyone who... 
15 Arab and Islamic countries welco... 
PM Modi calls for greater community... 
Cyclone Akvan: CM Mohan Majhi revie... 
Court permits accused research scho...